Tobias Raum

2.1k total citations
35 papers, 1.5k citations indexed

About

Tobias Raum is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Immunology. According to data from OpenAlex, Tobias Raum has authored 35 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Radiology, Nuclear Medicine and Imaging, 24 papers in Oncology and 17 papers in Immunology. Recurrent topics in Tobias Raum's work include Monoclonal and Polyclonal Antibodies Research (30 papers), CAR-T cell therapy research (17 papers) and Immunotherapy and Immune Responses (10 papers). Tobias Raum is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (30 papers), CAR-T cell therapy research (17 papers) and Immunotherapy and Immune Responses (10 papers). Tobias Raum collaborates with scholars based in Germany, United States and Switzerland. Tobias Raum's co-authors include Peter Kufer, Patrick A. Baeuerle, Matthias Friedrich, Ralf Lutterbuese, Doris Rau, Roman Kischel, Benno Rattel, Andreas Wolf, Gert Riethmüller and Susanne Mangold and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and The Journal of Immunology.

In The Last Decade

Tobias Raum

35 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Tobias Raum Germany 19 1.0k 716 635 471 112 35 1.5k
Carsten Reinhardt Germany 15 1.0k 1.0× 723 1.0× 655 1.0× 454 1.0× 94 0.8× 37 1.7k
Ezogelin Oflazoglu United States 18 809 0.8× 703 1.0× 727 1.1× 463 1.0× 96 0.9× 23 1.7k
Tom van Meerten Netherlands 17 812 0.8× 692 1.0× 487 0.8× 331 0.7× 152 1.4× 64 1.7k
Matthias Klinger Germany 13 1.4k 1.4× 684 1.0× 724 1.1× 397 0.8× 125 1.1× 23 1.9k
Mariele Goebeler Germany 10 1.2k 1.2× 633 0.9× 545 0.9× 300 0.6× 108 1.0× 22 1.6k
Roman Kischel Germany 20 1.2k 1.2× 819 1.1× 603 0.9× 513 1.1× 104 0.9× 45 1.7k
Idit Sagiv-Barfi United States 14 1.1k 1.1× 1.3k 1.8× 156 0.2× 371 0.8× 200 1.8× 32 1.9k
Christian Brandl Germany 13 1.8k 1.7× 911 1.3× 1.0k 1.6× 476 1.0× 156 1.4× 20 2.4k
Aniruddha Choudhury Sweden 20 909 0.9× 1.2k 1.6× 185 0.3× 460 1.0× 41 0.4× 38 1.7k
Ralf Lutterbüse Germany 11 681 0.7× 447 0.6× 580 0.9× 304 0.6× 74 0.7× 13 1.0k

Countries citing papers authored by Tobias Raum

Since Specialization
Citations

This map shows the geographic impact of Tobias Raum's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tobias Raum with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tobias Raum more than expected).

Fields of papers citing papers by Tobias Raum

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tobias Raum. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tobias Raum. The network helps show where Tobias Raum may publish in the future.

Co-authorship network of co-authors of Tobias Raum

This figure shows the co-authorship network connecting the top 25 collaborators of Tobias Raum. A scholar is included among the top collaborators of Tobias Raum based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tobias Raum. Tobias Raum is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Goldstein, Rebecca, Anja Henn, Petra Deegen, et al.. (2022). Abstract 6313: Evaluation of a dual CD123-FLT3 BiTE molecule for acute myeloid leukemia. Cancer Research. 82(12_Supplement). 6313–6313. 1 indexed citations
2.
Deegen, Petra, Oliver S. Thomas, Olivier Nolan-Stevaux, et al.. (2021). The PSMA-targeting Half-life Extended BiTE Therapy AMG 160 has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-resistant Prostate Cancer. Clinical Cancer Research. 27(10). 2928–2937. 58 indexed citations
3.
Giffin, Michael J., et al.. (2018). P3.12-03 Targeting DLL3 with AMG 757, a BiTE® Antibody Construct, and AMG 119, a CAR-T, for the Treatment of SCLC. Journal of Thoracic Oncology. 13(10). S971–S971. 30 indexed citations
4.
Roose, Kenny, Anouk Smet, Bert Schepens, et al.. (2017). Bispecific T cell engaging antibody constructs targeting a universally conserved part of the viral M2 ectodomain cure and prevent influenza A virus infection. Antiviral Research. 141. 155–164. 15 indexed citations
5.
Sternjak, Alexander, Fei Lee, Joachim Wahl, et al.. (2017). Abstract 3630: Preclinical evaluation of a BiTE® antibody construct with extended half-life that targets the tumor differentiation marker mesothelin. Cancer Research. 77(13_Supplement). 3630–3630. 1 indexed citations
6.
Raum, Tobias, et al.. (2015). Impact of Diverse Immune Evasion Mechanisms of Cancer Cells on T Cells Engaged by EpCAM/CD3-Bispecific Antibody Construct AMG 110. PLoS ONE. 10(10). e0141669–e0141669. 20 indexed citations
7.
Friedrich, Matthias, Anja Henn, Tobias Raum, et al.. (2014). Preclinical Characterization of AMG 330, a CD3/CD33-Bispecific T-Cell–Engaging Antibody with Potential for Treatment of Acute Myelogenous Leukemia. Molecular Cancer Therapeutics. 13(6). 1549–1557. 106 indexed citations
8.
Torisu‐Itakura, Hitoe, Myung‐Shin Sim, Reiko F. Irie, et al.. (2011). Redirected Lysis of Human Melanoma Cells by a MCSP/CD3-bispecific BiTE Antibody That Engages Patient-derived T Cells. Journal of Immunotherapy. 34(8). 597–605. 33 indexed citations
9.
Baeuerle, Patrick A., Matthias Friedrich, Alexander Murr, et al.. (2010). Highly Efficient Elimination of Colorectal Tumor-Initiating Cells by an EpCAM/CD3-Bispecific Antibody Engaging Human T Cells. PLoS ONE. 5(10). e13474–e13474. 67 indexed citations
10.
Münz, Markus, Alexander Murr, Doris Rau, et al.. (2010). Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies. Cancer Cell International. 10(1). 44–44. 107 indexed citations
11.
Lutterbuese, Ralf, Tobias Raum, Roman Kischel, et al.. (2010). T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells. Proceedings of the National Academy of Sciences. 107(28). 12605–12610. 123 indexed citations
12.
Raum, Tobias, Stefan Pflanz, Susanne Mangold, et al.. (2009). Human IgG1 antibodies antagonizing activating receptor NKG2D on natural killer cells. mAbs. 1(2). 115–127. 8 indexed citations
13.
Lutterbuese, Ralf, Tobias Raum, Roman Kischel, et al.. (2009). Potent Control of Tumor Growth by CEA/CD3-bispecific Single-chain Antibody Constructs That Are Not Competitively Inhibited by Soluble CEA. Journal of Immunotherapy. 32(4). 341–352. 64 indexed citations
14.
Amann, Maria, Grit Lorenczewski, Klaus Brischwein, et al.. (2009). Antitumor Activity of an EpCAM/CD3-bispecific BiTE Antibody During Long-term Treatment of Mice in the Absence of T-cell Anergy and Sustained Cytokine Release. Journal of Immunotherapy. 32(5). 452–464. 43 indexed citations
15.
Raum, Tobias, et al.. (2006). A human monoclonal IgG1 potently neutralizing the pro-inflammatory cytokine GM-CSF. Molecular Immunology. 44(5). 916–925. 22 indexed citations
16.
Volkland, Jörg, John S. Lumsden, Michael Mølhøj, et al.. (2006). A humanized monoclonal antibody against interleukin-2 that can inactivate the cytokine/receptor complex. Molecular Immunology. 44(7). 1743–1753. 3 indexed citations
17.
Brischwein, Klaus, Bernd Schlereth, Andreas Wolf, et al.. (2005). MT110: A novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors. Molecular Immunology. 43(8). 1129–1143. 212 indexed citations
18.
Mayer, Petra, Andreas Wolf, Frank Hanakam, et al.. (2002). In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment. International Journal of Cancer. 100(1). 101–110. 87 indexed citations
19.
20.
Raum, Tobias, Rudi Gruber, Gert Riethmüller, & Peter Kufer. (2001). Anti-self antibodies selected from a human IgD heavy chain repertoire: a novel approach to generate therapeutic human antibodies against tumor-associated differentiation antigens. Cancer Immunology Immunotherapy. 50(3). 141–150. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Carsten Reinhardt Breakdown of academic impact, for papers by Ezogelin Oflazoglu Breakdown of academic impact, for papers by Tom van Meerten Breakdown of academic impact, for papers by Matthias Klinger Breakdown of academic impact, for papers by Mariele Goebeler Breakdown of academic impact, for papers by Roman Kischel Breakdown of academic impact, for papers by Idit Sagiv-Barfi Breakdown of academic impact, for papers by Christian Brandl Breakdown of academic impact, for papers by Aniruddha Choudhury Breakdown of academic impact, for papers by Ralf Lutterbüse
Rankless by CCL
2026